A case report of postpartum idiopathic pulmonary arterial hypertension

被引:0
作者
Feng Hu [1 ]
Qianyao Lai [1 ]
Yuansheng Wu [2 ]
Shumei Li [1 ]
Lianglong Chen [1 ]
机构
[1] Fujian Medical University Union Hospital,Department of Cardiology, Fujian Cardiovascular Medical Center, Fujian Institute of Coronary Artery Disease
[2] Fujian Cardiovascular Research Center,School of Health
[3] Fujian Medical University,undefined
来源
Discover Medicine | / 1卷 / 1期
关键词
Pulmonary arterial hypertension; Postpartum; Case report;
D O I
10.1007/s44337-024-00036-4
中图分类号
学科分类号
摘要
Pulmonary arterial hypertension (PAH) is a pathophysiological condition characterized by pulmonary vascular remodeling and elevated vascular resistance, which may ultimately result in cardiovascular failure and sudden cardiac death. In recent years, the occurrence of pregnancy complicated by PAH has witnessed a notable increase, whereas the incidence of postpartum PAH is comparatively rare. This study presents a case involving a 39-year-old female who exhibited severe PAH, finally diagnosed as idiopathic pulmonary arterial hypertension, within two days postpartum. The diagnosis was made following a thorough clinical examination. The occurrence or exacerbation of PAH can be attributed to pregnancy. This case report emphasizes the significance of promptly initiating targeted therapy as an initial step in effectively managing patients and the criticality of conducting a thorough assessment of multidisciplinary collaboration in postpartum management. Prompt identification of PAH warrants early implementation of targeted therapy to enhance prognosis.
引用
收藏
相关论文
共 88 条
[1]  
Simonneau G(2019)Haemodynamic definitions and updated clinical classification of pulmonary hypertension Eur Respir J 53 1801913-475
[2]  
Montani D(2018)Pathophysiology and diagnosis of pulmonary hypertension due to left heart disease Front Med (Lausanne) 5 174-97
[3]  
Celermajer DS(2016)Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension Int J Mol Sci 17 761-47
[4]  
Charalampopoulos A(2014)Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report Chest 146 449-688
[5]  
Lewis R(2009)Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension Respir Res 10 129-2172
[6]  
Hickey P(2023)2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Eur Heart J 44 1312-119
[7]  
Leopold JA(2022)Chronic thromboembolic pulmonary hypertension: diagnosis, operability assessment and patient selection for pulmonary endarterectomy Ann Cardiothoracic Surg 11 82-1612
[8]  
Maron BA(2017)Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension BMC Pulm Med 17 44-475
[9]  
Taichman DB(2016)Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study BMC Cardiovasc Disord 16 201-1372
[10]  
Ornelas J(2015)Postpartum pulmonary hypertension Medicina 75 44-D72